Filing Flows › Humacyte (HUMA) › Recalls, complaints & regulation
Humacyte (HUMA): clinical trials
Humacyte (HUMA) beyond its filings: 4 active clinical trials.
Humacyte's latest quarter
Humacyte, Q2 2026: revenue $406K (+35% year over year), net loss $36.8M, operating cash flow −$22.1M. The chart follows the revenue to costs, profit and cash.
Questions
How many clinical trials does Humacyte have?
4 active studies on ClinicalTrials.gov, 2 in phase 3.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.